Contraindications to Progesterone-Only Pills
Progesterone-only pills (POPs) have remarkably few absolute contraindications, with current breast cancer being the only condition classified as an unacceptable health risk for initiation. 1
Absolute Contraindication
- Current breast cancer is the sole Category 4 (unacceptable health risk) contraindication to POPs 2
- This represents only 0.57-2.67% of women seeking contraceptive services 2
Clinical Situations Requiring Caution or Alternative Approaches
Cardiovascular Disease with Multidisciplinary Consultation Required
Women with a personal history of arterial events (coronary heart disease or stroke) should first be offered non-hormonal methods, preferably a copper IUD. If poorly tolerated, POPs may only be considered after multidisciplinary consultation. 1
Antiphospholipid Antibody Syndrome - Specific Progestin Considerations
For women with positive antiphospholipid antibodies:
- Strongly recommend POPs or levonorgestrel IUDs 3, 4
- Do NOT recommend depot medroxyprogesterone acetate (DMPA) due to thrombogenicity concerns 3, 4
- Insufficient data exists for the etonogestrel subdermal implant in this population 4
Systemic Lupus Erythematosus
- POPs are appropriate for SLE patients with moderate or severe disease activity 3, 4
- No unexpected increase in venous or arterial events was observed in SLE patients using progestin-only contraception 1
Key Clinical Advantages
POPs can be safely used in multiple situations where combined hormonal contraceptives are contraindicated:
- Personal history of venous thromboembolism 1
- Documented thrombophilia without clinical events 1
- Family history of thromboembolic events in first-degree relative before age 60 1
- Smokers over age 35 (any number of cigarettes) 1
- Migraine with aura
- Hypertension 5
Important Clinical Pearls
The overall prevalence of contraindications to POPs among reproductive-age women is remarkably low at 4.36% in the general population and only 2.29% among women specifically seeking contraceptive services. 2 This low contraindication rate supports the safety profile for potential over-the-counter access to POPs.
Unlike combined hormonal contraceptives, POPs do not increase myocardial infarction risk (RR 1.07,95% CI 0.62-1.83), making them suitable for women with cardiovascular risk factors. 1